These PLGA nanocapsules were delivered to HER2-overexpressing cancer cells in vivo using the HER2-recognizing scaffold polypeptide DARPin9_29 through two different drug delivery strategies (DDS), namely one-step DDS and two-step DDS (Figure 1). This evidence concerns the gene ERBB2 and cancer.